Valye reports for unlimited access

ENDRA Life Sciences Inc. focuses on developing and commercializing Thermo-Acoustic Enhanced Ultrasound (TAEUS) technology, which aims to improve ultrasound imaging quality and diagnostic capabilities. The company’s product portfolio includes devices targeting liver imaging applications, such as the MASLD TAEUS device and the TAEUS FLIP System. ENDRA has obtained CE mark approval for marketing in the European Union and is pursuing FDA regulatory clearance in the United States through a de novo classification process. The company relies on third-party manufacturers and is building sales and marketing capabilities to support commercialization. ENDRA also explores opportunities in digital assets and cryptocurrency as part of its portfolio expansion. The company has a history of operating losses and requires additional capital to support ongoing development and commercialization efforts.

Nuburu, Inc. specializes in high-powered blue laser technology products and related installation services. The company serves customers primarily in the United States, Europe, and Asia. Revenue recognition follows standard accounting principles, with product sales recognized at a point in time and installation services recognized over time. Despite historical revenue generation, Nuburu did not record revenue in 2025 and continues to operate at a net loss, reflecting its developmental stage and ongoing commercialization efforts. The company has taken cost reduction measures including employee furloughs, which have impacted operations. Nuburu is actively pursuing strategic initiatives including acquisitions, joint ventures, and investments to expand its technology applications, especially in defense and security sectors. It has also engaged in multiple financing activities to support its operations and growth plans. The company faced a trading halt due to low stock price but implemented a reverse stock split to regain compliance with NYSE American listing standards. It is currently under a compliance plan with the exchange.

Alpha Cognition Inc. operates as a biopharmaceutical company dedicated to developing treatments for neurodegenerative diseases, with a primary focus on Alzheimer's disease. The company’s flagship product, ZUNVEYL (benzgalantamine), is a next-generation acetylcholinesterase inhibitor approved by the FDA in July 2024 and commercially launched in March 2025. ZUNVEYL is designed to provide symptomatic relief for mild to moderate Alzheimer's disease with a differentiated mechanism and improved tolerability profile, particularly minimizing gastrointestinal side effects. The company targets the long-term care market in the U.S., leveraging a specialty sales force and engaging with Medicare payors and pharmacy benefit managers to expand formulary coverage. Alpha Cognition also pursues pre-clinical development of additional formulations and combination therapies, including sublingual ALPHA-1062 for mild traumatic brain injury and combination with memantine for moderate-to-severe Alzheimer's disease. The company maintains strong liquidity with $66 million in cash and equivalents as of year-end 2025 but has incurred significant net losses since inception. It faces competition from established symptomatic treatments and emerging disease-modifying therapies but aims to differentiate through clinical benefits and tolerability.

Edible Garden AG Inc operates in the indoor agriculture and consumer packaged goods sectors, focusing on fresh produce and sustainable agriculture products. The company sells primarily to national and local supermarket chains, with a high concentration of revenue from a few customers. It owns or controls growing facilities in Michigan and New Jersey and uses third-party contract growers. The company has developed proprietary forecasting software (GreenThumb) to manage supply and demand. Recent strategic initiatives include launching new product lines such as Pickle Party™, Pulp®, and Kick. Sports Nutrition, expanding distribution through major retailers, acquiring NaturalShrimp assets, and developing a ready-to-drink beverage manufacturing platform at its Iowa facility. The company has a history of significant net losses and liquidity challenges, with auditors expressing substantial doubt about its ability to continue as a going concern. Edible Garden faces competitive pressures, low industry margins, customer concentration risks, and environmental risks related to weather and climate change.

Alset Inc. is a diversified holding company engaged through subsidiaries in real estate development, digital transformation technologies, biohealth activities, and consumer products. Its operations span the United States, Singapore, Hong Kong, Australia, South Korea, and China. The company manages its principal businesses primarily through its 85.8% owned subsidiary, Alset International Limited, publicly traded on the Singapore Stock Exchange. The real estate segment focuses on land subdivision developments near Houston, Texas, including the Lakes at Black Oak project and the Alset Villas community, with a portfolio of 132 single-family rental homes equipped with smart home and solar technologies. The digital transformation technology segment provides B2B solutions in e-commerce, collaboration, social networking, and incorporates advanced technologies such as AI and metaverse services. The biohealth segment develops, manufactures, licenses, and distributes health-related products, with operations in Korea and the US. The company completed the acquisition of New Energy Asia Pacific Inc. in 2025, expanding into the distribution of all-electric special-purpose and transportation vehicles, charging stations, and batteries. Alset Inc. reported revenue of approximately $4.5 million and a net loss of about $47.4 million for the fiscal year ended December 31, 2025, with strong liquidity ratios indicating a solid short-term financial position. The company operates with a holding company structure and depends on earnings and distributions from its subsidiaries to meet obligations. It faces competitive and operational risks and is actively managing a material weakness in internal controls related to staffing.[S1][S2]

Fortress Biotech, Inc. operates as a biopharmaceutical company through a network of subsidiaries and partner companies engaged in the development and commercialization of pharmaceutical products across various therapeutic areas. The company provides business, scientific, regulatory, legal, and financial support to its subsidiaries, which include publicly traded entities such as Journey Medical Corporation, Mustang Bio, and Avenue Therapeutics, as well as private subsidiaries. Fortress's business model centers on acquiring or licensing intellectual property and advancing product candidates through development, regulatory approval, and commercialization. The company generates revenue primarily through product sales by its subsidiaries, collaboration agreements, and milestone payments. Fortress also raises capital through equity and debt offerings, warrant exercises, and asset sales to fund operations and growth initiatives. The company maintains contractual arrangements with specialty pharmacies and commercial payers, including rebates and product return policies consistent with industry standards. Fortress's consolidated financial position as of December 31, 2025, reflects total assets of approximately $185.5 million and stockholders' equity of $62.2 million, supported by liquidity measures indicating operational funding sufficiency for at least 12 months post-filing.

Decoy Therapeutics Inc. is a biotechnology company at the pre-clinical stage, specializing in peptide conjugate therapeutics engineered through its proprietary IMP 3 ACT™ platform. This platform leverages machine learning and artificial intelligence alongside fast-flow synthesis to rapidly design and manufacture peptide conjugates targeting serious unmet medical needs, primarily in infectious diseases and oncology. The company emerged from a merger completed in November 2025 between Salarius Pharmaceuticals and Legacy Decoy, resulting in a combined entity renamed Decoy Therapeutics Inc. in January 2026. The merger integrated complementary drug development approaches, including legacy small molecule clinical candidates and the novel peptide conjugate platform. The company has no approved products or revenues and is advancing multiple drug development programs, including a lead pan-Coronavirus antiviral prophylactic targeting immunocompromised patients, supported by significant non-dilutive funding. It plans to file an IND application in the first half of 2027 and is pursuing strategic partnerships and platform manufacturing capabilities. The company maintains Nasdaq listing compliance through reverse stock splits and regulatory appeals and reported a net loss of $12.5 million for the year ended December 31, 2025, with cash and equivalents of approximately $10.7 million.

Kodiak Sciences Inc. develops next-generation retinal therapeutics using its proprietary Antibody Biopolymer Conjugate (ABC) platform. Founded in 2009, the company focuses on preventing and treating major causes of blindness through biologic therapies with enhanced durability and efficacy. Its lead product candidate, tarcocimab tedromer (Zenkuda), is an anti-VEGF therapy designed for extended ocular half-life and flexible dosing intervals from 1 to 6 months. Kodiak has completed multiple Phase 3 studies demonstrating efficacy in diabetic retinopathy, retinal vein occlusion, and wet age-related macular degeneration, with ongoing pivotal trials. Additional candidates include KSI-501, a bispecific anti-IL-6/VEGF therapy, and KSI-101 targeting inflammation-related macular edema. The company has invested in commercial-scale manufacturing capabilities and retains global commercialization rights. Kodiak is in the clinical stage with no approved products and has incurred significant net losses since inception.

Femasys Inc. is a medical device company specializing in women-specific medical products, including non-surgical permanent birth control and intratubal insemination solutions. The company has expanded its commercial presence in Europe through partnerships and has received regulatory certifications such as the CE Mark for its FemBloc system. Femasys has raised capital through public offerings to support product development and commercialization efforts. The company reported a net loss for the year ended December 31, 2025, and maintains liquidity with a current ratio above 4. It faces Nasdaq listing compliance challenges related to minimum bid price and market value requirements, with ongoing efforts to address these issues.

ADM Endeavors, Inc., through its subsidiary Just Right Products, operates a diverse vertically integrated business focused on promotional products and uniforms. The company offers a wide range of logoed products via retail sales, screen printing, embroidery, digital production, and import wholesale sourcing. It serves various customers including government entities, businesses, schools, and municipalities. The company has expanded its government contracts significantly and has developed a strong online presence supported by SEO and web marketing. In 2025, ADM Endeavors completed construction of a new corporate headquarters and production facility in Fort Worth, Texas, which expands production capacity by up to 5.8 times and supports fulfillment services. The company is navigating industry challenges such as tariffs affecting the school uniform market by sourcing its own branded uniforms and capitalizing on discounted inventory. Financially, the company reported positive net income and maintains liquidity with a current ratio above 1.0 as of the end of 2025.

Scientific Industries, Inc. is a manufacturer and marketer of benchtop laboratory equipment and bioprocessing systems. The company operates two segments: Benchtop Laboratory Equipment, which includes balances, scales, pill counters, and moisture analyzers sold under the Torbal® and VIVID® brands; and Bioprocessing Systems, which offers smart sensor-based products and software analytics marketed under the DOTS brand. The company sold its Genie Division in August 2025 but continues to operate the Torbal Division. Bioprocessing Systems operations are based primarily in Germany, with a direct sales force and distributor network. The company holds patents for key products and invests heavily in product development. Major customers and vendors represent significant portions of sales and purchases. The company faces competition from larger companies and operates in a niche market with limited backlog and no material seasonality.

Callan JMB Inc. operates as a vertically integrated logistics and fulfillment company focused on thermal management logistics solutions for the life sciences sector. Its services include emergency preparedness and response, specialty temperature-regulating reusable packaging, fulfillment services, and advanced monitoring technology (Sentry) to ensure the integrity of temperature-sensitive biological products. The company leverages proprietary technology and a broad North American footprint to serve a diversified customer base, including government agencies and Fortune 500 firms. Callan JMB completed its IPO in 2025 and continues to expand through strategic contracts and joint ventures, emphasizing environmental sustainability and technological innovation.

American Rebel Holdings Inc is a lifestyle brand focused on American patriotism, offering products including branded safes, personal security items, apparel, and a light beer brand. The company acquired Champion Safe Company in 2022, significantly expanding its safe manufacturing and sales operations. Its safes are primarily made with U.S.-sourced steel and are marketed for home and personal security. The company launched American Rebel Light Beer in September 2024, distributing it across multiple U.S. states through partnerships and e-commerce. American Rebel also pursues brand licensing opportunities and has made strategic minority investments to broaden its product portfolio and operational reach. The company emphasizes a patriotic brand identity and engages in marketing through motorsports, music festivals, and retail partnerships. Financially, the company reported a net loss and limited liquidity as of the end of 2025, with ongoing capital needs to support its growth strategy.

CPI Aerostructures, Inc. (CPI Aero) is a U.S.-based aerospace and defense manufacturer with over 45 years of experience. The company produces structural assemblies, integrated systems, and provides kitting and MRO services primarily for military and commercial aerospace customers. CPI Aero serves as a prime contractor to the U.S. Department of Defense and as a Tier 1 subcontractor to leading defense primes such as Lockheed Martin, RTX Corporation, and Northrop Grumman. Its product offerings span aerostructures (wing structures, engine inlets, doors), aerosystems (pod structures, radar housings), complex tube bending, specialty welding, and electrical cables and harnesses. The company emphasizes build-to-print manufacturing and engineering services, supporting customer programs with program management, supply chain management, and quality assurance. CPI Aero competes with larger Tier 1 suppliers and internal manufacturing arms of customers, leveraging its combination of large contractor capabilities and small company flexibility. The company maintains a diversified customer base with approximately 80% of revenue from defense prime subcontracts, 9% from commercial contracts, and 11% from direct government sales. CPI Aero's backlog stood at approximately $504.5 million at the end of 2025, reflecting a mix of funded and unfunded contracts. The company reported a net loss for fiscal 2025 and maintains a current ratio of 1.89, indicating liquidity to meet short-term obligations [S1][S2].

TMC the metals Co Inc. develops polymetallic nodules from the deep seabed in the Clarion Clipperton Zone, a large area in the Eastern Pacific Ocean rich in critical metals such as nickel, copper, cobalt, manganese, and rare earth elements. The company aims to create a sustainable metal supply chain to meet rising demand in strategic sectors including semiconductors, energy, defense, and batteries. TMC is advancing its projects through regulatory pathways under the U.S. Deep Seabed Hard Mineral Resources Act and maintains contracts with the International Seabed Authority. It has established strategic partnerships with leading offshore engineering, smelting, refining, and technology companies to develop commercial-scale collection and processing systems. The company is developing a near-zero solid waste processing flowsheet and is exploring onshore processing facilities in the United States. TMC reported modest revenue and significant net losses as it remains in the development phase, with liquidity supported by cash reserves. The company faces risks related to regulatory approvals, financing, operational execution, market acceptance of novel products, and legal proceedings.

Copley Acquisition Corp is a Cayman Islands exempted company formed as a special purpose acquisition company (SPAC) with the objective of effecting a merger, share exchange, asset acquisition, share purchase, reorganization, or similar business combination. The company focuses on technology and lifestyle sectors, targeting businesses primarily in the Asia Pacific region (excluding the PRC) and North America. It completed its initial public offering in May 2025, raising gross proceeds of $172.5 million, which are held in a trust account to fund a future business combination. The company has not yet identified or entered into a definitive agreement with any target business. Its management team has significant experience in financial services and technology industries and leverages a broad network for deal sourcing. The company is subject to NYSE rules requiring the initial business combination to have a fair market value of at least 80% of the trust account balance. If it fails to complete a business combination within the prescribed timeframe (up to 24 months), it will liquidate and redeem public shares.

Afya Ltd is a Brazilian education company focused on medical and health-related education services. It operates through three segments: Undergraduate education offering medical and health science courses; Continuing Education providing medical specialization and residency preparation via digital and in-person formats; and Medical Practice Solutions delivering clinical management and decision support services to healthcare professionals. The company generates revenue primarily from tuition fees, digital content subscriptions, and related educational services. Afya has expanded through acquisitions and organic growth, increasing its student base and service offerings. The company reported steady revenue and net income growth in 2025, supported by operational efficiencies and increased enrollment. It maintains a strong liquidity position and invests in capital expenditures to support growth and infrastructure.

NewGenIvf Group Ltd operates assisted reproductive services (ARS) clinics primarily in Asia Pacific, including Thailand, Cambodia, and Kyrgyzstan. The company provides IVF treatment services and fertility referral services, with a strategic focus on expanding its client base and service offerings across the region. Revenue decreased from $5.4 million in 2024 to $4.7 million in 2025, with IVF treatment revenue declining and fertility referral services emerging as a new revenue stream. The company reported net income of $9.7 million in 2025, influenced by a significant bargain purchase gain from acquisitions. NewGenIvf is also pursuing diversification through investments in digital assets and real estate, including a $45 million investment in UAE real estate and a $30 million investment in Solana blockchain technology. The company has undertaken multiple reverse stock splits to consolidate shares and has a share repurchase program. It faces risks related to regulatory environments, international travel conditions affecting client access, and market liquidity of digital assets.

Odysseus Holdings Ltd, incorporated in August 2025 in Jersey, Channel Islands, is a holding company that owns CoinShares International Limited and its subsidiaries. CoinShares International Limited operates as a leading digital asset investment business. The company completed a business combination that resulted in all business activities being conducted through CoinShares International Limited. The company’s shares were previously listed on the Nasdaq First North Growth Market in Stockholm. The company’s principal offices are in Jersey, with a U.S. agent for service of process in New York. Financially, as of June 30, 2025, the company had cash and cash equivalents of $60.2 million, total indebtedness of $29.9 million, and total equity of $394.3 million, resulting in total capitalization of $424.1 million on a pro forma combined basis. The company’s financial statements have been audited by recognized accounting firms. Risk factors are disclosed in the Proxy Statement/Prospectus incorporated by reference [S1].

Seanergy Maritime Holdings Corp. is an international dry bulk shipping company specializing in the transportation of dry bulk commodities worldwide. The company owns or finance leases a fleet of 18 Capesize and 2 Newcastlemax vessels, with a total cargo capacity of approximately 3.6 million dwt and an average fleet age of about 14.7 years. It has five newbuilding vessels under construction and has agreed to sell one Capesize vessel. The fleet is primarily employed under long-term time charters with rates linked to the Baltic Capesize Index, with some vessels having fixed floor rates plus profit-sharing. Seanergy provides technical management for most vessels through its wholly owned subsidiary and contracts commercial management services to an independent third party. The company has a history of share repurchases and a dividend policy with consistent quarterly payments. It is engaged in sustainability initiatives including retrofitting vessels to use alternative fuels. Financially, as of December 31, 2025, Seanergy reported revenues of $158.1 million, net income of $21.2 million, and basic EPS of $1.02, with liquidity ratios indicating moderate short-term financial flexibility.

Tenaris S.A. operates as a leading global supplier of steel tubes and related services, primarily for the energy sector and other industrial applications. The company’s comprehensive disclosures in its 2025 Annual Report on Form 20-F detail its business segments, products, production processes, sales and marketing strategies, competitive strengths, and organizational structure. Tenaris reported nearly $12 billion in revenue and close to $2 billion in net income for the full year 2025, supported by a strong liquidity position with a current ratio of 3.87 as of year-end 2025. The company has recently adjusted its capital allocation strategy by terminating the second tranche of a $1.2 billion share buyback program amid market volatility. Ongoing news coverage provides insights into quarterly earnings and market activity, contributing to a well-documented public profile [S1][S2][N3][N2][N1].

GDEV Inc. is a foreign private issuer incorporated in the British Virgin Islands with its principal executive office located in Limassol, Cyprus. The company files annual and periodic reports with the SEC, including Form 20-F and Form 6-K. It prepares its financial statements in accordance with IFRS and has its financials audited by KPMG Somekh Chaikin. The company reported $404.3 million in revenue and $69.3 million in net income for the fiscal year ended December 31, 2025, with basic EPS of $3.82. As of the same date, it held $62.9 million in cash and cash equivalents, with a current ratio of 0.67, indicating liquidity below 1.0. The CEO and Chairman increased his ownership stake to 37.0% in a private share purchase transaction in March 2026. GDEV maintains cybersecurity risk management programs and insider trading compliance policies. The company is not currently treated as a Passive Foreign Investment Company for U.S. tax purposes but this status is subject to annual review. Recent news coverage references GDEV in the context of consumer discretionary stock performance but lacks direct operational updates [S1][S2][N8].

POET TECHNOLOGIES INC. is a technology company incorporated in Ontario, Canada, with operations across North America and Asia. The company invests in research and development equipment and patents, focusing on advanced technology products. Its financial disclosures indicate early-stage revenue generation with substantial net losses and moderate liquidity. The company faces operational risks from regulatory, environmental, and geopolitical factors, as well as market volatility related to its stock and capital structure.

GeoPark Ltd operates as an independent oil and gas company with a focus on Latin America, particularly Colombia and Argentina. The company has a diversified portfolio including conventional and unconventional assets. Its business model emphasizes disciplined capital allocation, operational efficiency, and growth through both organic development and strategic acquisitions. GeoPark's governance is structured under Bermuda law, with a nine-member board overseeing business conduct and shareholder rights. The company maintains a strong liquidity position and has recently secured significant institutional investment to support its growth plans. Key assets include the Llanos 34 block in Colombia and unconventional assets in the Neuquén Basin, Argentina, where it is advancing its Vaca Muerta platform [S1][S2][N1][N8].

Nanobiotix S.A. is a biotechnology company focused on developing novel oncology therapies. The company is actively conducting clinical trials, including a Phase 2 study of its JNJ-1900 candidate for non-small cell lung cancer (NSCLC) and pancreatic cancer. Nanobiotix has reported favorable clinical results and is pursuing further evaluation of its therapies. The company maintains regulatory compliance through annual Form 20-F filings and periodic Form 6-K reports with the SEC. Financial disclosures as of December 31, 2025, show revenue generation alongside net losses, reflecting ongoing investment in research and development. Liquidity metrics suggest the company maintains sufficient short-term assets to cover current liabilities. Recent corporate actions include share acquisition transactions and public clarifications regarding takeover rumors.

Ternium S.A. operates primarily in the steel and mining sectors across Latin America and the southern United States. The company produces a broad range of steel products including slabs, hot and cold rolled coils, coated products, and tubular products, serving manufacturing and construction industries. It operates two main steelmaking technologies: blast furnace/basic oxygen furnace and direct reduction/electric arc furnace, with ongoing investments in low carbon emission technologies. Ternium supports its value chain through programs like ProPymes, aiding SMEs in productivity and export capacity. The company has a significant industrial presence in Mexico, Brazil, Argentina, and Colombia, with integrated production and distribution networks. It reported $15.6 billion in net sales and $303 million in net income for 2025, with a strong liquidity position and ongoing capital investments focused on facility expansion and modernization.

Galmed Pharmaceuticals Ltd. is an Israeli biopharmaceutical company incorporated in 2013, focused on the development of Aramchol, a drug candidate targeting liver diseases such as NASH and fibrosis, with ongoing exploration into oncological and cardiometabolic indications. The company operates through wholly-owned subsidiaries in Malta, Israel, and the UK. Galmed has no marketed products and has historically funded its operations through equity offerings. The company has reported consistent operating losses and an accumulated deficit exceeding $210 million as of the end of 2025. Its financial position as of December 31, 2025, shows cash and equivalents of approximately $4 million, short-term deposits and marketable securities totaling over $14 million, and current liabilities of $2.8 million, resulting in a current ratio of 6.55. The company’s shares trade on the Nasdaq Capital Market under the symbol GLMD. Recent corporate actions include a reverse stock split and equity financing arrangements. Clinical development milestones include positive early-stage trial results for Aramchol Meglumine [S1][N1][N3][N4][N5][N6][S2].

DoubleDown Interactive Co., Ltd. is a publicly traded company listed on NASDAQ under the ticker DDI. The company operates in the digital gaming industry, focusing on social casino games and iGaming. Its business model includes revenue generation from game sales and in-game purchases across multiple geographic markets, including the U.S., Canada, Europe, and other international regions. The company has expanded its portfolio through acquisitions, notably the purchase of WHOW Games GmbH in 2025. Financially, the company maintains strong liquidity and profitability metrics, with detailed disclosures in its SEC filings. The company’s governance includes independent directors and shareholder-approved remuneration limits. Recent developments include revenue growth in the iGaming segment and strategic investments in marketing and product development.

Planet Image International Ltd operates through subsidiaries manufacturing compatible toner cartridges for laser printers, selling primarily in the U.S., Europe, China, and Brazil. The company’s products are sold via offline ODM customers, offline dealers, and online retail under self-owned brands. It holds a significant patent portfolio and invests in research and development to maintain product quality and market competitiveness. The company is listed on Nasdaq under ticker YIBO and has a dual-class share structure with enhanced voting rights for Class B shares.

SEALSQ Corp operates in the secure semiconductor and post-quantum cryptography sector, providing hardware-embedded security solutions, custom integrated circuit design services, and trust services. The company has a three-phase quantum product roadmap starting with the QS7001 post-quantum cryptography hardware platform launched in late 2025, followed by mid-term development of custom ASICs and long-term secure system solutions including chiplet-based Hardware Security Modules. SEALSQ's acquisition of IC'Alps in 2025 enhanced its ASIC design capabilities and expanded its engineering team. The company has a broad geographic footprint with strategic growth in the US, EMEA, and Asia Pacific, supported by multiple design wins and a robust customer pipeline. SEALSQ also manages a Quantum Fund to invest in startups in quantum computing and AI-driven semiconductor technologies. Financially, SEALSQ reported $18.25 million in revenue and a net loss of $34.19 million for 2025, with a strong liquidity position as of year-end. The company is engaged in several strategic partnerships and joint ventures, including initiatives in satellite-based quantum-secure communications and semiconductor design centers.

Rail Vision Ltd. is an Israeli technology company specializing in advanced AI-integrated sensing systems for railway safety. Founded in 2016, the company develops and commercializes proprietary multi-spectral electro-optic platforms that combine visible-light and thermal cameras with machine learning algorithms to detect and classify obstacles on and around railway tracks. Its flagship products include the MainLine System, designed for long-distance freight and passenger trains, and the ShuntingYard System, tailored for rail yard operations. Rail Vision also offers the D.A.S.H. cloud-based platform to analyze operational data and enhance decision-making for rail operators. The company targets a growing global market driven by increasing demand for railway safety, operational efficiency, and automation, including autonomous trains. Rail Vision has established strategic partnerships and pilot projects with major rail operators in Israel, Latin America, the United States, and India, demonstrating its technology's capabilities under diverse operational conditions. The company reported a net loss in 2025 but maintains strong liquidity to support ongoing commercialization efforts [S1][N1][N3][N5].

Xtra-Gold Resources Corp is a publicly traded gold exploration company with operations centered in Ghana, West Africa. Its primary asset is the Kibi Gold Project, where it conducts extensive exploration drilling to identify and expand gold mineralization zones. The company operates through consulting arrangements with key executives who oversee exploration, financial, and administrative functions. Xtra-Gold funds its activities through a combination of cash reserves, proceeds from gold sales, investment income, and equity financing. It maintains a strong liquidity position and has a history of share repurchases. The company’s shares trade on the Toronto Stock Exchange and OTC Bulletin Board. It has a board of directors with a majority of independent members and established governance committees. The company does not currently pay dividends and focuses on advancing its exploration projects.

Intelligent Group Ltd operates as a professional Financial PR services provider in Hong Kong, offering services such as press conferences, investor targeting, shareholder meeting support, and crisis management. The company focuses on facilitating effective communication between its clients and the public and investors to enhance market perception. Its revenue streams include recurring Financial PR services, project-based services like roadshows and listing ceremonies, and one-off PR services such as press release writing. The company’s financial performance is closely tied to capital market conditions in Hong Kong and is subject to competitive pressures from both large and smaller firms in the Financial PR sector. It maintains strong liquidity and has implemented cybersecurity risk management policies overseen by its board.

HCW Biologics Inc. is a Delaware-based biotechnology company focused on developing novel therapeutic molecules for in vivo applications, including CAR-T cell therapies and autoimmune disorder treatments. The company has proprietary molecules such as HCW11-006, HCW9302, and HCW9206, with ongoing research and clinical-stage development. HCW Biologics has established strategic partnerships, including an exclusive worldwide license agreement with WY Biotech for HCW11-006 and an option for HCW9302's Greater China rights. The company has engaged in capital raising activities through equity offerings and warrant transactions. Financially, HCW Biologics reported a net loss and liquidity constraints as of the fiscal year ended December 31, 2025, but has regained compliance with Nasdaq listing rules.

American Shared Hospital Services is a provider of stereotactic radiosurgery and advanced radiation therapy equipment and services. The company operates through two segments: medical equipment leasing and direct patient services. The leasing segment includes fee-per-use and revenue sharing contracts for Gamma Knife and PBRT systems leased to hospitals. The direct patient services segment involves ownership and operation of radiation therapy facilities in Peru, Ecuador, Mexico, and Rhode Island. The company’s revenue is driven by the number of sites, procedure volume, and reimbursement rates. The company faces customer concentration risks, with a few customers accounting for a large portion of revenue and accounts receivable. The company’s equipment is primarily sourced from Elekta. The company reported a net loss in 2025, primarily due to operational challenges in the direct patient segment and equipment downtime. Liquidity ratios as of December 31, 2025, show a current ratio below 1, indicating potential liquidity constraints. The company’s credit facilities mature in April 2026, with ongoing discussions about extension [S1].

Dawson Geophysical Company specializes in land-based seismic data acquisition and processing services, including 2-D, 3-D, and multi-component seismic data, serving major and independent oil and gas companies as well as multi-client data library providers. The company operates primarily in the lower 48 U.S. states and Canada, with two reportable segments: U.S. operations and Canada operations. Contracts are typically awarded through competitive bidding or client negotiations and are structured as either turnkey or term agreements. Turnkey contracts offer higher profit potential but involve greater operational risk, while term contracts provide more consistent revenue streams. The company faces competition from several established seismic service providers and smaller local firms. Dawson's workforce includes approximately 269 full-time employees as of the end of 2025. The company is controlled by Wilks Brothers, LLC, which holds about 80% of voting power and board control, affecting corporate governance and strategic decisions. Recent years have seen net losses, but 2025 showed improved operating results and cash flow. The company has engaged in equipment purchase agreements to upgrade seismic technology and maintains multiple facilities in Texas and Canada. Revenue is concentrated among a few key clients, with the largest client accounting for over half of revenues in 2025. The business is sensitive to fluctuations in oil and natural gas prices and exploration activity, which impact demand for seismic services.